Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus | Zendy

Benjamin M. Scirica | Zendy; Deepak L. Bhatt | Zendy; Eugene Braunwald | Zendy; Philippe Gabríel Steg | Zendy; Jaime A. Davidson | Zendy; Boaz Hirshberg | Zendy; Peter Öhman | Zendy; Robert Frederich | Zendy; Stephen D. Wiviott | Zendy; Elaine Hoffman | Zendy; Matthew A. Cavender | Zendy; Jacob A. Udell | Zendy; Nihar R. Desai | Zendy; Ofri Mosenzon | Zendy; Darren K. McGuire | Zendy; Kausik K. Ray | Zendy; Lawrence A. Leiter | Zendy; Itamar Raz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

Author(s) -

Benjamin M. Scirica,

Deepak L. Bhatt,

Eugene Braunwald,

Philippe Gabríel Steg,

Jaime A. Davidson,

Boaz Hirshberg,

Peter Öhman,

Robert Frederich,

Stephen D. Wiviott,

Elaine Hoffman,

Matthew A. Cavender,

Jacob A. Udell,

Nihar R. Desai,

Ofri Mosenzon,

Darren K. McGuire,

Kausik K. Ray,

Lawrence A. Leiter,

Itamar Raz

Publication year - 2013

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1307684

Subject(s) - saxagliptin , medicine , hazard ratio , myocardial infarction , heart failure , placebo , stroke (engine) , type 2 diabetes , unstable angina , clinical endpoint , diabetes mellitus , confidence interval , randomized controlled trial , sitagliptin , endocrinology , mechanical engineering , alternative medicine , pathology , engineering

The cardiovascular safety and efficacy of many current antihyperglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research